Methylphenidate Stada (Methylphenidate Hydrochloride)

Methylphenidate Stada is a central nervous system stimulant used in the management of attention‑deficit/hyperactivity disorder and narcolepsy.

• Childhood ADHD: improves attention, reduces hyperactivity and impulsivity, supporting better academic performance and behavior in school‑aged children.
• Adult ADHD: enhances concentration, organization and executive function, aiding work productivity and daily task management in adolescents and adults.
• Narcolepsy: decreases excessive daytime sleepiness, reduces cataplexy episodes and promotes sustained wakefulness.

• Methylphenidate inhibits the reuptake of dopamine and norepinephrine by blocking their transporters in neuronal synapses. This increases the extracellular concentrations of these catecholamines, enhancing neurotransmission in brain regions that regulate attention, impulse control and wakefulness, such as the prefrontal cortex and the hypothalamic arousal pathways. The elevated catecholamine activity modulates cortical and subcortical circuits, leading to improved signal‑to‑noise ratio for task‑relevant stimuli.

Methylphenidate Stada may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Insomnia: difficulty falling or staying asleep.
• Decreased appetite: reduced hunger leading to weight loss.
• Stomach pain: abdominal discomfort or cramps.
• Headache: mild to moderate head pain.

Serious or Rare Side Effects

• Cardiovascular events: hypertension, tachycardia or arrhythmias.
• Psychosis: hallucinations or delusional thinking.
• Severe allergic reaction: rash, swelling, or anaphylaxis.

Before prescribing Methylphenidate Stada, clinicians should consider several precautionary measures to ensure patient safety.

• Cardiovascular assessment: evaluate heart disease history and monitor blood pressure and pulse.
• Psychiatric monitoring: watch for emergence of psychosis, mania or severe mood changes.
• Growth monitoring: regularly assess weight and height in pediatric patients.
• Abuse potential: assess risk of misuse or diversion, especially in individuals with substance‑use history.
• Store at room temperature: keep in original container, protect from moisture and heat.

Methylphenidate Stada can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

• Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis when combined.
• Tricyclic antidepressants: may increase cardiovascular side effects.

Moderate Interactions (Monitor Closely)

• Antihypertensives: possible reduction in blood‑pressure‑lowering effect.
• Anticonvulsants: may alter methylphenidate plasma concentrations.
• CYP2D6 inhibitors: can raise methylphenidate levels, increasing adverse‑event risk.